Fateh Mann

🗞️ Grown Rogue Closes Initial Transactions to Enter New York with Planned Acquisition of PharmaCann's New York License and Assets $GRUSF $GRIN.CN @GrownRogue 🔥-take: Grown Rogue just pulled off a low-risk, high-upside land grab, snagging a big vertical New York platform (serious indoor canopy + four stores) from a struggling PharmaCann via project financing that mostly keeps the risk off their balance sheet. If they execute the turnaround, this becomes a cash-flow machine in one of the last big undersupplied flower markets. 🗣️ MANAGEMENT COMMENTARY Obie Strickler @ObieStrickler, CEO of Grown Rogue @GrownRogue: "We believe New York regulators have proactively improved the regulatory framework and enforcement efforts, creating a more vibrant, entrepreneurial-led environment that is actively shifting more of the market's demand through regulated channels. That backdrop, coupled with what we believe is a shortage of quality indoor flower, led us to aggressively pursue entry into the New York market when this opportunity became available. We view this move as transformational for Grown Rogue given the production scale and verticality, while remaining squarely in our wheelhouse: the efficient production of craft-quality flower. PharmaCann developed substantial, well-built infrastructure, and we're excited about the potential to build with the local team and make these assets thrive. As co-founders and significant shareholders, Sarah and I are particularly mindful of how we deploy capital. The project-based financing structure allows us to pursue this opportunity with limited and prudent balance sheet risk, particularly given the history of the New York market." "Our immediate focus is preserving the value of the platform, which includes supporting the four Verilife stores and ramping the production of flower. We intend to retain many of the local PharmaCann team while bringing our culture and passion to revitalize these operations. We are proud of our Rogue Valley heritage and excited to bring what we do best – deliver amazing flower and flower-forward products to the great people of New York." Josh Rosen @analyst_exec, Chief Strategy Officer of Grown Rogue "A core part of my mandate has been identifying opportunities where Grown Rogue's cultivation and operating capabilities can create outsized value. New York quickly stood out as a highly desirable market for our capabilities, with limited in-state indoor flower canopy and more than 700 dispensaries. We believe the existing PharmaCann platform gives us a strong foundation, while the operational reset provides an opportunity to build the business around the disciplines that have driven Grown Rogue's success in other markets. Importantly, we believe our New York entry will meet or exceed our criteria of generating returns on incremental invested capital of greater than 75%." 🤖 ANALYSIS **Grown Rogue is using a capital-efficient, project-financed structure to enter New York by taking operational control of (and planning to acquire) PharmaCann’s New York license and assets (PCNY), adding significant indoor/greenhouse canopy plus four retail doors while ring-fencing most balance-sheet risk.** The August 21, 2026 announcement details initial transactions (exclusivity, Goods & Services Agreement/GSA, lease arrangements, and funding) via the newly formed Grown Rogue New York, LLC (GRNY), a 51/49 joint venture. Definitive purchase agreements are expected within about four weeks, followed by New York Office of Cannabis Management (OCM) regulatory approvals for change of control. The structure deliberately avoids a prolonged shutdown of the assets and associated job losses. ### Key Deal Terms and Assets - **Assets**: Hamptonburgh cultivation and manufacturing facility (~24,000 sq ft indoor flower canopy + 16,000 sq ft light-deprivation greenhouse flower canopy, plus substantial post-harvest, ethanol/hydrocarbon extraction, and commercial kitchen space) and four Verilife dispensaries (two combination adult-use/medical in the Albany and Syracuse metros; two medical-only in the Buffalo metro and Bronx/NYC). - **Historical performance** (pre-slowdown): Facility averaged >2,000 lbs of flower per month before production substantially slowed in early 2026. Dispensaries averaged $1.7–2.0 million in aggregate monthly sales over the prior 18 months. Revenue was skewed toward the medical channel and first-party products; ~80% of wholesale revenue came from flower and pre-rolls. - **Purchase price**: Anticipated ~$4.5 million (including inventory adjustment at GSA execution), with ~$3 million payable upon regulatory approval of the change of control. - **Interim operations**: GRNY manages day-to-day operations (including the four stores) under the GSA, funds operating needs/losses, and provides a secured loan of up to $9 million to PCNY for production ramp, modest capex, inventory replenishment, and working capital. GRNY will be disclosed as a True Party of Interest. There is also a master lease (with an Innovative Industrial Properties affiliate) and sublease structure for the facility. Management is focused on retaining current staff and rehiring former employees. **Financing (project-based, up to $15 million commitment)**: A capital partner invested $10 million for a 49% preferred equity interest in GRNY (Grown Rogue retains 51%). Preferred equity receives priority annual distributions ($1 million in year 1, $2 million thereafter); Grown Rogue receives a matching second-priority distribution, with remaining cash flow split 49/51. The preferred is convertible (at the partner’s option) into Grown Rogue subordinate voting shares at escalating prices starting at $0.55 (would be ~18.2 million shares / ~7% dilution if converted at announcement levels), with higher prices in later years. Grown Rogue has a repurchase right under certain return-of-capital conditions before the fifth anniversary. The same partner committed an additional $5 million drawable 15% term loan (or Grown Rogue may seek alternatives), plus a commitment fee of 300,000 shares and warrants. Total project costs (acquisition + capex + working capital) are estimated at ~$12 million, providing a cushion. Mindset Capital (Grown Rogue’s largest shareholder) introduced the partner and is advising. ### Strategic Fit and How It Expands the Business Grown Rogue is a flower-forward operator focused on craft-quality, consistent, efficiently produced indoor flower, with a track record of both new builds and “fixer-upper” turnarounds (e.g., prior Illinois activity involving another former PharmaCann facility). Management explicitly frames New York as attractive due to regulatory/enforcement improvements that are shifting more demand into legal channels, a perceived shortage of quality indoor flower, and a large retail footprint (>700 dispensaries). CEO Obie Strickler called the opportunity “transformational” for production scale and verticality while remaining “squarely in our wheelhouse.” CSO Josh Rosen highlighted expected returns on incremental invested capital >75% (the company’s stated target threshold). **Expansion impact**: - **New major market + capacity scale**: Adds a large, vertical platform in one of the U.S.’s largest and still-growing cannabis markets (New York legal sales have been expanding rapidly, with flower remaining a core category and ongoing illicit-to-legal shifts). The ~40,000 sq ft of combined flower canopy is meaningful relative to Grown Rogue’s existing footprint (Oregon, Michigan, New Jersey, plus Illinois and Minnesota projects). It immediately gives retail doors and manufacturing capabilities, enabling first-party product emphasis. - **Vertical integration and revenue diversification**: Moves beyond primarily wholesale/cultivation in core markets into owned retail (Verilife) plus cultivation/manufacturing. Historical PCNY mix (medical skew + high first-party) aligns with opportunities to push Grown Rogue genetics/flower and capture more margin as adult-use grows. - **Capital discipline and limited parent risk**: Project financing and the JV structure keep most capital needs and preferred returns at the GRNY level rather than heavily leveraging the parent balance sheet. This matches the company’s pattern of returns-focused, often partner-supported market entries. - **Operational upside via turnaround playbook**: Identified ~$20 million in annual cost reductions (majority from lease/property adjustments). Management projects after-tax operating cash flow positive within nine months and ~$600,000 monthly after-tax operating cash flow within 18 months (assumptions include lease savings, successful 6–9 month production ramp, staffing, demand/pricing, and potential 280E relief by 2027). Applying Grown Rogue’s cultivation disciplines to a previously high-output facility that was slowed is consistent with prior “fixer-upper” approach. **Near-term focus**: Preserve platform value, support the four stores (potential modest disruption from reduced first-party inventory during ramp), revitalize Hamptonburgh production, and integrate culture/operations while finalizing docs and pursuing approvals. ### Risks and Caveats The deal is not yet closed—definitive agreements and OCM change-of-control approvals remain outstanding. Production ramp will take time; interim retail performance could soften. New York still faces pricing pressure, competition (including illicit), regulatory evolution, and tax dynamics. Achieving the full cost savings and cash-flow targets depends on execution, lease effectiveness, market conditions, and other factors outlined in the company’s forward-looking assumptions. The JV/preferred structure will add GAAP complexity (management has committed to transparency on underlying performance). Dilution risk exists if the preferred converts, and preferred distributions prioritize the partner. ### Conclusion Overall, this is a logical, high-conviction expansion that leverages Grown Rogue’s core strengths in quality flower production and operational turnaround while using project capital to enter a large, still-maturing market with meaningful scale and verticality at relatively modest parent risk. Success hinges on regulatory clearance, production ramp execution, and realizing the identified cost and operational improvements. 🌿 Cannabis ETFs: 🌎 $YOLO 🇺🇸 $MSOS ir.grownrogue.com/news-event…